ClinicalTrials.gg
CompletedNCT03121820Updated Oct 29, 2018Results posted

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

A Phase 1 interventional study of Memantinol tablets, 20 mg and Akatinol Memantine® tablets, 20 mg in Bioequivalence, AUC, Cmax, Pharmacokinetics, sponsored by Geropharm. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-29.

Sponsored by Geropharm · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2016, registered Apr 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg tablets in normal healthy subjects

Read the detailed description

Study to evaluate the bioequivalence of orally administered memantinol preparations, film-coated tablets, 20 mg

02

Conditions studied

  • Bioequivalence, AUC, Cmax, Pharmacokinetics
03

In context

Lead sponsor

Geropharm is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Healthy male and female subjects aged 18 to 45 years.
  • Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.
  • Have a between 18,5 and 27 kg/m2.
  • Females must have a negative pregnancy test.
  • Subjects must use, with their partner, methods of highly effective ; if the Hormonal contraceptives was used they must canceled have at least 2 month before the study.

from the time of IMP administration until 3 months after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  • History of serious allergic problems/events
  • Medicinal intolerance.
  • History of allergic reactions to memantine or investigator's product components
  • Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrinal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.
  • Acute infectious diseases in less than 4 weeks before the start of the study.
  • Subjects who have taken medication 4 weeks preceding before the study.
  • Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).
  • Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.
  • History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).
  • Smokers.
  • Participation in other clinical training is less than than for 3 months before the study.
  • Lack of signed form.
  • or vital signs abnormalities ().
  • Positive testing for alcohol, drugs, pregnancy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Memantinol tablets, 20 mg

    Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC "GEROPHARM", Russia - test)

    Drug: Memantinol tablets, 20 mg

  • Active comparator
    Akatinol Memantine® tablets, 20 mg

    Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH \& Co. KGaA, Germany - reference)

    Drug: Akatinol Memantine® tablets, 20 mg

Interventions

  • Bioequivalence Memantine Hydrochloride (JSC "GEROPHARM", Russia) 20 mg film-coated tablets fasting condition

    Also known as: memantine

  • Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition

    Also known as: memantine

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))

    Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH \& Co. KGaA, Germany)

    Time frame: 0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

  2. Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)

    Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH \& Co. KGaA, Germany)

    Time frame: 0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

07

Results

Posted Oct 29, 2018

Participant flow

Participants recruited at GKB № 15 im. O. M. Filatova Public Healthcare Institution of Department of health care of Moscow, Russian Federation between October and November 2016

First Period
Participant flow — First Period
MilestoneMemantinol First, Then Akatinol Memantine®Akatinol Memantine® First, Then Memantinol
Started99
Completed99
Not completed00
Second Period (After Washout)
Participant flow — Second Period (After Washout)
MilestoneMemantinol First, Then Akatinol Memantine®Akatinol Memantine® First, Then Memantinol
Started99
Completed99
Not completed00

Outcome measures

PrimaryPharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))

Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH \& Co. KGaA, Germany)

Time frame:
0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))
ng*h/mLMemantinol Tablets, 20 mgAkatinol Memantine® Tablets, 20 mg
Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))1920.362 ± 449.2892096.669 ± 537.147
Statistical analysis
  • Memantinol Tablets, 20 mg vs Akatinol Memantine® Tablets, 20 mg · Test/Ref Geometric mean ratio x 100 · p = 0.05 · Test/ref geometric mean ratio x 100: 93.8 · 90% CI 88.25 to 99.77Bioequivalence is established when 90% Confidence Interval falls within 80.00 % -125.00 %.
PrimaryPharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)

Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC "GEROPHARM", Russia) and Akatinol Memantine® (Merz Pharma GmbH \& Co. KGaA, Germany)

Time frame:
0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)
ng/mLMemantinol Tablets, 20 mgAkatinol Memantine® Tablets, 20 mg
Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)34.617 ± 8.30237.578 ± 8.858
Statistical analysis
  • Memantinol Tablets, 20 mg vs Akatinol Memantine® Tablets, 20 mg · Test/Ref Geometric mean ratio x 100 · p = 0.05 · Test/ref geometric mean ratio x 100: 92.3 · 90% CI 86.37 to 98.55Bioequivalence is established when 90% Confidence Interval falls within 80.00 % -125.00 %.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantinol Tablets, 20 mg—0/18 (0%)2/18 (11.1%)
Akatinol Memantine® Tablets, 20 mg—0/18 (0%)2/18 (11.1%)
Most frequent other events
Most frequent other events
EventMemantinol Tablets, 20 mgAkatinol Memantine® Tablets, 20 mg
DizzinessNervous system disorders2/182/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Memantinol First, Then Akatinol Memantine®Akatinol Memantine® First, Then MemantinolTotal
<=18 years000
Between 18 and 65 years9918
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Memantinol First, Then Akatinol Memantine®Akatinol Memantine® First, Then MemantinolTotal
Female549
Male459
08

Study locations

1 site
  • City Clinical Hospital № 15 named. O.M.filatova
    Moscow, Russian Federation
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Nov 2016, 1 month.

Results were first posted in Oct 2018, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
Apr 20, 2017
StartActual
Oct 11, 2016
Primary completionActual
Nov 19, 2016
CompletionActual
Nov 19, 2016
Results first posted
Oct 29, 2018
Last update
Oct 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03121820
Lead sponsor
Geropharm
Responsible party
Sponsor
First posted
Apr 20, 2017
Start date
Oct 11, 2016
Primary completion
Nov 19, 2016
Completion
Nov 19, 2016
Results posted
Oct 29, 2018
Last update
Oct 29, 2018

Study contacts

Igor Makarenko, MD, PhD
study chair · Igor.Makarenko@geropharm.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion